Literature DB >> 8109920

In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis.

R T Mehta1, A Keyhani, T J McQueen, B Rosenbaum, K V Rolston, J J Tarrand.   

Abstract

We compared MICs and MBCs of various free- and liposome-incorporated antimicrobial agents against several patient isolates of Mycobacterium avium-M. intracellulare complex and certain American Type Culture Collection strains of M. avium, M. intracellulare, and Mycobacterium tuberculosis. Seven of 19 agents were selected for incorporation into liposomes. The MICs of these agents for 50 and 90% of isolates tested (MIC50s and MIC90s, respectively) ranged from 0.5 to 62 micrograms/ml. Members of the M. avium-M. intracellulare complex were resistant to killing by most of the other agents tested in the free form. However, clofazimine, resorcinomycin A, and PD 117558 showed complete killing of bacteria at concentrations ranging from 8 to 31 micrograms/ml, represented as MBC90s. Among the liposome-incorporated agents, clofazimine and resorcinomycin A had the highest killing effects (MBC90s, 8 and 16 micrograms/ml, respectively). Furthermore, both free and liposome-incorporated clofazimine had equivalent growth-inhibitory and killing effects on all American Type Culture Collection strains of M. avium, M. intracellulare, and M. tuberculosis tested. These results show that the antibacterial activities of certain drugs, particularly those of clofazimine and resorcinomycin, were maintained after the drugs were incorporated into liposomes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8109920      PMCID: PMC192745          DOI: 10.1128/AAC.37.12.2584

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Treatment of infections in patients with the acquired immunodeficiency syndrome.

Authors:  D Armstrong; J W Gold; J Dryjanski; E Whimbey; B Polsky; C Hawkins; A E Brown; E Bernard; T E Kiehn
Journal:  Ann Intern Med       Date:  1985-11       Impact factor: 25.391

2.  A comparison of in vitro toxicity and antifungal efficacy of membrane-active drugs after liposome encapsulation.

Authors:  R T Mehta; R L Hopfer; R L Juliano; G Lopez-Berestein
Journal:  Sel Cancer Ther       Date:  1989

3.  Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin.

Authors:  L E Bermudez; M Wu; L S Young
Journal:  J Infect Dis       Date:  1987-09       Impact factor: 5.226

Review 4.  The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis.

Authors:  S Omura
Journal:  Bacteriol Rev       Date:  1976-09

Review 5.  NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations.

Authors:  A S Fauci; A M Macher; D L Longo; H C Lane; A H Rook; H Masur; E P Gelmann
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

6.  Basis for lack of drug susceptibility of atypical mycobacteria.

Authors:  H L David
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

7.  In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.

Authors:  K V Rolston; D H Ho; B LeBlanc; G P Bodey
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

8.  Lanthiopeptin, a new peptide antibiotic. Production, isolation and properties of lanthiopeptin.

Authors:  N Naruse; O Tenmyo; K Tomita; M Konishi; T Miyaki; H Kawaguchi; K Fukase; T Wakamiya; T Shiba
Journal:  J Antibiot (Tokyo)       Date:  1989-06       Impact factor: 2.649

9.  Clofazimine and other rimino-compounds: minimal inhibitory and minimal bactericidal concentrations at different pHs for Mycobacterium avium complex.

Authors:  P J Lindholm-Levy; L B Heifets
Journal:  Tubercle       Date:  1988-09

10.  Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells.

Authors:  E J Bowman; A Siebers; K Altendorf
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

View more
  12 in total

1.  Enhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium-Mycobacterium intracellulare complex after liposome encapsulation.

Authors:  R Gomez-Flores; R Hsia; R Tamez-Guerra; R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

Review 2.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

3.  Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.

Authors:  J Conley; H Yang; T Wilson; K Blasetti; V Di Ninno; G Schnell; J P Wong
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 4.  World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Authors:  Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

5.  Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine.

Authors:  L B Adams; I Sinha; S G Franzblau; J L Krahenbuhl; R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  Rapid screening of natural products for antimycobacterial activity by using luciferase-expressing strains of Mycobacterium bovis BCG and Mycobacterium intracellulare.

Authors:  R M Shawar; D J Humble; J M Van Dalfsen; C K Stover; M J Hickey; S Steele; L A Mitscher; W Baker
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection.

Authors:  R G Kansal; R Gomez-Flores; I Sinha; R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

8.  Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.

Authors:  R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection.

Authors:  Y K Oh; D E Nix; R M Straubinger
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex.

Authors:  L C Ellis; C A Benson; G I Koenig; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.